LTR Pharma Limited (ASX:LTP)

Market Cap	54.29M
Revenue (ttm)	499.71K
Net Income (ttm)	-6.82M
Shares Out	180.98M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70,567
Average Volume	112,138
Open	0.2850
Previous Close	0.2900
Day's Range	0.2850 - 0.3000
52-Week Range	0.2700 - 2.1600
Beta	n/a
RSI	45.45
Earnings Date	Aug 29, 2025

About LTR Pharma

LTR Pharma Limited, a biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: LTP